Advanced Enzyme Technologies Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹215 Cr +16.2% YoYSee revenue, profit and what management said. You are viewing Q1 FY26.
AE

Advanced Enzyme Technologies Ltd

Q1 FY26Pharmaceuticals & Biotechnology

Advanced Enzyme Technologies Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹186Cr
+20% YoY
+11.4% QoQ
Net profit
₹40Cr
+14.3% YoY
+48.1% QoQ
Margin
30%
−3 pp YoY
+3 pp QoQ
Price₹300
Market cap₹3.7K Cr
P/E24.0

The short version

The company targets double-digit growth over the longer run but is cautious about predicting exact figures due to product mix and market cycles. The company targets sustained double-digit growth over the medium to long term rather than very high short-term spikes.

From Advanced Enzyme Technologies Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • The company targets double-digit growth over the longer run but is cautious about predicting exact figures due to product mix and market cycles.
  • Medium-term outlook expects maintaining or improving current momentum, with hopes to touch about 80% capacity utilization within 2 years before next capacity expansion.
  • Focus remains on segments like Human Nutrition (notably Pharma and Probiotics) and Animal Nutrition, with some new products and biocatalyst applications under development.
  • Regulatory changes favoring green chemistry and biocatalysts, especially in developed countries, could positively impact demand.
  • Sales growth in probiotics is part of blends with enzymes; difficult to segregate but seen as a growth area.

2 more points from Advanced Enzyme Technologies Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Advanced Enzyme Technologies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The company has been investing significantly in a new R&D facility at Nashik, with about INR48 crores already spent; this expense is currently under work in progress and not included in regular R&D expenditure.
  • The new R&D center is expected to be commissioned by the last quarter of this fiscal year.
  • Management is open to capacity expansions whenever capacity utilization approaches around 80%, which they hope to reach in about 2 years, indicating future capex in manufacturing capacity.
  • There is mention of ongoing product development and research across various segments, suggesting continuous investment in innovation.

2 more points from Advanced Enzyme Technologies Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Advanced Enzyme Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Some relevant insights related to business outlook and sales pipeline are: - Growth is driven by ongoing projects from the last 1-2 years in both export and domestic markets beginning to materialize. - Management is optimistic about sustaining growth in key segments like Human Nutrition and Animal Nutrition. - The company is focused on expanding business in these areas while working on new sectors and products, including probiotics and biocatalysts. - R&D efforts and patent filings aim to convert into future sales, though exact timelines or order visibility are unclear.

2 more points from Advanced Enzyme Technologies Ltd's call on order book

Create a free account to keep reading this call

Advanced Enzyme Technologies Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Advanced Enzyme Technologies Ltd Q1 FY26 results — key figures

Advanced Enzyme Technologies Ltd Q1 FY26 reported results vs Q1 FY25, ₹ crore
₹ CrQ1 FY26Q1 FY25YoYQ4 FY25QoQ
Revenue186155+20%167+11.4%
Operating profit (EBITDA)5651+9.8%46+21.7%
Operating margin30%33%-3 pp27%+3 pp
Profit before tax5549+12.2%43+27.9%
Net profit (PAT)4035+14.3%27+48.1%
EPS (₹)3.573.05+17%2.37+50.6%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹215 Cr, net profit ₹51 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • RPG Life Sciences (Q1 FY26)

    168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • SMS Pharmaceuticals (Q1 FY26)

    Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…

  • Morepen Laboratories (Q1 FY26)

    Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • NGL Fine Chem (Q1 FY26)

    Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Advanced Enzyme Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Advanced Enzyme Technologies Ltd Q1 FY26 results?

The company targets double-digit growth over the longer run but is cautious about predicting exact figures due to product mix and market cycles. The company targets sustained double-digit growth over the medium to long term rather than very high short-term spikes.

What is Advanced Enzyme Technologies Ltd share price analysis?

Advanced Enzyme Technologies Ltd currently shows a neutral. The stock trades at a P/E of 24.0 with a market cap of ₹3,726 Cr. Investors should review the full earnings analysis for detailed insights.

Is Advanced Enzyme Technologies Ltd planning capital expenditure?

The company has been investing significantly in a new R&D facility at Nashik, with about INR48 crores already spent; this expense is currently under work in progress and not included in regular R&D expenditure.

Keep Advanced Enzyme Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.